Pharmacokinetic Interaction Study of Ketamine, Cannabidiol, and Cobicistat in Healthy Volunteers

The primary objective of this study is to evaluate the pharmacokinetic interaction between ketamine, cannabidiol, and cobicistat. This investigation is clinically relevant for understanding how these substances influence the metabolic profile and plasma concentrations of one another. There are no secondary objectives reported.

The sponsor did not provide the total number of participants. The study population consists of healthy volunteers of both male and female genders. The age range for these subjects is categorized under code 3.

This Phase 2 clinical trial is designed to investigate the interactions between ketamine, cannabidiol, and cobicistat. The research methodology utilizes a controlled study design to evaluate these pharmacological components. The study process begins with a screening visit to determine eligibility. Following screening, participants undergo scheduled study visits to monitor the effects and interactions of the substances. The sequence concludes with an end-of-study visit. The estimated duration of the trial, including recruitment, spans from February 2026 to December 2026. Early termination of participation may occur based on predefined clinical criteria or study protocols.

The efficacy assessment for this Phase 2 clinical trial involves evaluating parameters in healthy volunteers. Due to the absence of specified endpoints or measurement methodologies in the provided data, no specific clinical parameters, scales, or assessment schedules are defined.